68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma

• Status: Recruiting
• Trial end date: 2024-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Chemokine receptor-4 (CXCR4) is overexpressed in multiple myeloma (MM) cells. 68Ga-pentixafor is a radio-labled tracer for CXCR4 . 68Ga-pentixafor PET/CT has shown good diagnostic performance in MM. But an exchange of Ga3+ by Lu3+ or Y3+ will lead to a significant loss of CXCR4 affinity. Investigators conduct this prospective study to evaluate the diagnostic performance of 68Ga-pentixather compared with 68Ga-pentixafor, in order to parallel 68Ga-pentixather and 177Lu/90Y-pentixather in theranostics of MM.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital

Criteria

Inclusion Criteria:

1. Suspected or confirmed untreated multiple myeloma (MM), relapsed MM, MM in remission

2. Signed written consent

Exclusion Criteria:

1. pregnancy

2. breastfeeding

3. known allergy against pentixather or pentixafor

4. any medical condition that in the opinion of the investigator, may significantly interfere with study compliance.